UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Bullous systemic lupus erythematosus

Author
Dan Lipsker, MD, PhD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Bullous systemic lupus erythematosus (BSLE) is a rare autoimmune blistering disorder that typically manifests as an acute vesiculobullous eruption in a patient with known systemic lupus erythematosus (SLE). Rarely, BSLE is the initial clinical manifestation of SLE.

The differential diagnosis of blistering in patients with SLE is broad; therefore, careful assessment is necessary to confirm the diagnosis. The classic histologic and immunofluorescence findings of BSLE are separation within the dermal-epidermal junction, a neutrophilic infiltrate in the superficial dermis, immunoglobulin G (IgG) deposition at the dermal-epidermal junction, and antibody deposition on the dermal side of basement membrane zone-split skin. Anti-collagen VII autoantibodies are the serologic marker of BSLE. A rapid response to dapsone therapy is characteristic.

The clinical manifestations, diagnosis, and management of BSLE will be reviewed here. An overview of blistering skin disorders and a summary of the cutaneous manifestations of lupus erythematosus are provided separately. (See "Approach to the patient with cutaneous blisters" and "Overview of cutaneous lupus erythematosus".)

EPIDEMIOLOGY

BSLE is a rare disorder for which epidemiologic data are limited [1,2]. In accordance with the epidemiology of systemic lupus erythematosus, BSLE is more frequent in females than in males. BSLE usually occurs in adults between the ages of 20 and 40 years; however, children and older adults also may be affected [3].  

PATHOGENESIS

The clinical manifestations of BSLE result from the disruption of epidermal-dermal adhesion secondary to antibody formation against type VII collagen, the major component of the anchoring fibrils in the cutaneous basement membrane zone (figure 1). Anchoring fibrils play a critical role in the attachment of the epidermis to the dermis. (See "Epidermolysis bullosa acquisita", section on 'Type VII collagen'.)

                    
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Mar 24, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131:48.
  2. De D, Khullar G, Handa S, et al. Clinical, demographic and immunopathological spectrum of subepidermal autoimmune bullous diseases at a tertiary center: A 1-year audit. Indian J Dermatol Venereol Leprol 2016; 82:358.
  3. Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol 2014; 15:517.
  4. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol 1999; 135:569.
  5. Herrero-González JE, Mascaró JM Jr, Herrero C, et al. Autoantibodies from patients with BSLE inducing recruitment of leukocytes to the dermoepidermal junction and subepidermal splits in cryosections of human skin. Arch Dermatol 2006; 142:1513.
  6. Recke A, Sitaru C, Vidarsson G, et al. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun 2010; 34:435.
  7. Seo JY, Byun HJ, Cho KH, Lee EB. Methimazole-induced bullous systemic lupus erythematosus: a case report. J Korean Med Sci 2012; 27:818.
  8. Gammon WR, Heise ER, Burke WA, et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988; 91:228.
  9. Barbosa WS, Rodarte CM, Guerra JG, et al. Bullous systemic lupus erythematosus: differential diagnosis with dermatitis herpetiformis. An Bras Dermatol 2011; 86:S92.
  10. Lourenço DM, Gomes RC, Aikawa NE, et al. Childhood-onset bullous systemic lupus erythematosus. Lupus 2014; 23:1422.
  11. Tincopa M, Puttgen KB, Sule S, et al. Bullous lupus: an unusual initial presentation of systemic lupus erythematosus in an adolescent girl. Pediatr Dermatol 2010; 27:373.
  12. Burke KR, Green BP, Meyerle J. Bullous lupus in an 18-year-old. Pediatr Dermatol 2011; 28:483.
  13. Mekouar F, Hammi S, Elomri N, Ghafir D. Bullous systemic lupus erythematosus. Intern Med 2011; 50:1445.
  14. Hamminga EA, Vermeer MH. Bullous systemic lupus erythematosus responding to mycophenolate mofetil. Eur J Dermatol 2010; 20:844.
  15. Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003; 12:63.
  16. Nico MM, Lourenço SV. Multiple blisters along the lip vermilion are a clue to bullous lupus erythematosus. Acta Derm Venereol 2012; 92:404.
  17. Yogarajah M, Sivasambu B, Jaffe EA. Bullous systemic lupus erythematosus associated with esophagitis dissecans superficialis. Case Rep Rheumatol 2015; 2015:930683.
  18. Camisa C, Sharma HM. Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature. J Am Acad Dermatol 1983; 9:924.
  19. Camisa C, Grimwood RE. Indirect immunofluorescence in vesiculobullous eruption of systemic lupus erythematosus. J Invest Dermatol 1986; 86:606.
  20. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol 2004; 22:129.
  21. Ackerman AB, Chongchitnant N, Sanchez J, et al. Histologic Diagnosis of Inflammatory Skin Diseases: An Algorithmic Method Based on Pattern Analysis, 2nd ed, Williams & Wilkins, Baltimore, MD 1997.
  22. Tsuchida T, Furue M, Kashiwado T, Ishibashi Y. Bullous systemic lupus erythematosus with cutaneous mucinosis and leukocytoclastic vasculitis. J Am Acad Dermatol 1994; 31:387.
  23. Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112.
  24. Woodley DT, Sarret Y, Briggaman RA. Autoimmunity to type VII collagen. Semin Dermatol 1991; 10:232.
  25. Gammon WR, Murrell DF, Jenison MW, et al. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol 1993; 100:618.
  26. Grabell DA, Matthews LA, Yancey KB, Chong BF. Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. JAMA Dermatol 2015; 151:539.
  27. Tani M, Shimizu R, Ban M, et al. Systemic lupus erythematosus with vesiculobullous lesions. Immunoelectron microscopic studies. Arch Dermatol 1984; 120:1497.
  28. Kim JH, Kim SC. Epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 2013; 27:1204.
  29. Merklen-Djafri C, Bessis D, Frances C, et al. Blisters and Loss of Epidermis in Patients With Lupus Erythematosus: A Clinicopathological Study of 22 Patients. Medicine (Baltimore) 2015; 94:e2102.
  30. Lipsker D, Saurat JH. Neutrophilic cutaneous lupus erythematosus. At the edge between innate and acquired immunity? Dermatology 2008; 216:283.
  31. Gleason BC, Zembowicz A, Granter SR. Non-bullous neutrophilic dermatosis: an uncommon dermatologic manifestation in patients with lupus erythematosus. J Cutan Pathol 2006; 33:721.
  32. Duan L, Chen L, Zhong S, et al. Treatment of Bullous Systemic Lupus Erythematosus. J Immunol Res 2015; 2015:167064.
  33. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97:165.
  34. Pehr K. Mycophenolate mofetil and erythromycin for bullous lupus erythematosus of childhood. J Cutan Med Surg 2012; 16:50.
  35. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol 2011; 17:142.